A clinical-stage immuno-oncology company developing novel cancer immunotherapy technologies, including IFx-2.0 as an innate immune agonist to overcome resistance to checkpoint inhibitors, and Delta receptor technology for targeting Myeloid Derived Suppressor Cells.